Doximity (DOCS) Stock Nearly Doubles Intraday - 'LinkedIn for Doctors' AI Claims and a Short Squeeze Collide

What Happened

After the closing bell on August 6, Doximity (NYSE: DOCS), the professional network and software platform built for U.S. physicians, reported fiscal 2027 first-quarter results covering April through June 2026. Revenue came in at $156.6 million, up 7% year-over-year and above the high end of the company's own guidance range. Adjusted EBITDA reached $74.8 million, a 48% margin. Adjusted earnings per share of $0.29, however, fell short of what Wall Street had modeled. On its face, this was an unremarkable, mixed quarter — a modest revenue beat paired with a soft bottom-line number.

The market's reaction was anything but unremarkable. In after-hours trading following the report, Doximity shares spiked from a prior close of $20.66 to nearly triple that level before paring back some of the gain, and the volatility carried into Friday's regular session, where the stock at one point traded up roughly 130% before cooling to somewhere in the 45-70% range as the day wore on. Headlines from CNBC and other major outlets described the move simply as "Doximity shares double" — and by the scale of the single-day swing, it ranks among the largest individual healthcare-stock moves of the year.

Alongside the results, the company raised its full fiscal-year 2027 revenue guidance to a range of $671-681 million, up from a prior $664-676 million, and guided adjusted EBITDA to $309-329 million, implying a roughly 47% margin. A 7% top-line growth rate is respectable but hardly the kind of number that typically doubles a company's market value in a day. The real story was in two specific comments management made on the earnings call.

Why a 7% Revenue Beat Triggered a Near-Doubling of the Stock

The first driver was CEO Jeff Tangney's commentary on Doximity's AI search business. "We're earning more than 10 times per search in revenue than it costs to run," he told analysts on the call. The claim signaled that Doximity's AI-powered clinical search product — the tool physicians use to look up drug information, treatment guidelines, and patient-education content — isn't a cost center subsidized by the core business, but a proven, high-margin revenue engine in its own right. What made the comment especially notable is that AI search revenue was essentially zero in this specific quarter. Management explained that the bulk of contracted AI search revenue won't be recognized under accounting rules until fiscal Q3, later in the year. In other words, investors weren't reacting to a number already on the books — they were pricing in a future revenue stream the company says is already contracted and simply awaiting recognition. That dynamic resembles how a large order backlog can move a stock before it ever shows up in reported sales: the market is weighting the credibility of a proven, contracted business model more heavily than the trailing quarter's actual figures.

The second driver was an independent benchmark result on clinical AI performance. Researchers from Stanford, Harvard, and the ARISE network — a group focused on AI safety in medicine — built a benchmark called NOHARM that ran 1,100 real clinical cases through multiple AI systems and collected roughly 13,000 physician evaluations to measure the risk of each model producing harmful or incorrect medical guidance. Doximity said its in-house clinical assistant, Doximity Ask, topped the benchmark with a 4.8% error rate. Tangney went further, noting that Anthropic's Claude Fable 5 model recorded a 13.6% error rate on the same test, and attributed the gap to Doximity's proprietary medical data and physician-review workflow. It's worth noting this was a third-party academic evaluation rather than a benchmark Doximity commissioned itself, which is part of why the market treated it as more than a marketing talking point. That said, it remains a single benchmark taken at one point in time, and AI model performance can shift meaningfully with subsequent updates or different evaluation methodology — a caveat worth keeping in mind before treating any one benchmark as a durable competitive moat.

Together, the two comments triggered a wave of price-target increases. Canaccord raised its target to $36 from $30 while maintaining a Buy rating, BMO Capital lifted its target to $30 from $20, and Piper Sandler moved to $47 from $42. Multiple firms raising targets by 20-50% in a single session suggests analysts, too, are treating the AI commentary less as a one-off headline and more as a re-rating of the underlying business model.

A third factor, separate from earnings or the AI narrative, also amplified the move: a short squeeze. Roughly 17% of Doximity's tradable float was reportedly sold short heading into the print — a notably elevated level for the healthcare sector, reflecting real skepticism among some investors about the stock's valuation or growth trajectory. When the AI-related news landed harder than expected, short sellers facing mounting losses were forced to buy back shares to close out their positions, which tends to amplify a stock's initial move well beyond what the underlying fundamentals alone would justify. That mechanic likely explains much of why the stock briefly traded up more than 130% intraday before settling into the 45-70% range — squeeze-driven spikes typically unwind at least partially as forced buying subsides, and that's roughly the pattern that played out here.

What to Take Away From This

• Revenue and earnings growth rates alone rarely explain a near-doubling of a stock. Doximity's 7% revenue growth this quarter was ordinary by itself; it was management's forward-looking commentary — paired with third-party validation — that moved the stock this dramatically. When reading an earnings report, pay as much attention to how management frames the future as to the reported numbers themselves.
• Heavily shorted stocks can see outsized, mechanically amplified rallies on good news. With 17% of the float sold short, an unexpected positive catalyst can trigger a short squeeze that pushes a stock's move well past what fundamentals alone would justify — and that kind of gain often partially unwinds as the squeeze fades.
• Independent, third-party benchmarks tend to carry more market weight than a company's own marketing claims. Doximity's NOHARM result came from outside academic researchers, which is part of why it moved analyst price targets. Still, a single benchmark taken at one moment in time doesn't guarantee a lasting competitive advantage, especially in a fast-moving field like AI.
• Contracted but not-yet-recognized revenue can move a stock well before it appears in reported financials. Doximity's AI search revenue was effectively zero this quarter, yet the promise of future recognition was enough to move the stock sharply. That kind of forward-looking value is real, but it remains unconfirmed until it actually shows up in the numbers.
• Chasing a stock during its most volatile hours is risky. A move that swings from up 130% to up 45% within the same session is a sign that a meaningful part of the rally is squeeze-driven rather than fundamentals-driven, and further sharp swings are common as that unwind plays out.

For a related look at how AI-driven demand narratives can swing a stock sharply around an earnings report, see our coverage of Cloudflare's Q2 earnings surprise, where a raised outlook produced a comparably large single-day move.

Sources

This article synthesizes and analyzes the reporting below in our own words — it is not a reproduction of the original text. For the latest figures, please refer to the original sources and the company's official earnings release.

• Doximity shares double. Here's what's driving it - CNBC
• Why Doximity Stock is Up More Than 70% in After-Hours Trading Thursday - Benzinga
• Doximity Announces Fiscal 2027 First Quarter Financial Results - Business Wire
• DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets - Stocktwits

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly — always verify the latest data yourself before making any investment decision.